Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8(+) T-Cell Responses, (vol 78, pg 152, 2010)

Bibliographic Details
Main Authors:	Reyes-Sandoval, A, Berthoud, T, Alder, N, Siani, L, Gilbert, S, Nicosia, A, Colloca, S, Cortese, R, Hill, A
Format:	Journal article
Published:	2011

Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses.
by: Reyes-Sandoval, A, et al.
Published: (2010)

Erratum: Prime-boost immunization with adenoviral and modified vaccinia virus ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses
by: Reyes-Sandoval, A, et al.
Published: (2011)

Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates
by: Capone, S, et al.
Published: (2010)

Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates.
by: Capone, S, et al.
Published: (2010)

Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells.
by: Scriba, T, et al.
Published: (2010)

PHASE I TRIAL OF A HIGHLY IMMUNOGENIC AND DURABLE T-CELL VACCINE FOR HEPATITIS C VIRUS BASED ON NOVEL, RARE, ADENOVIRAL VECTORS
by: Barnes, E, et al.
Published: (2011)

Increased detection of proliferating, polyfunctional, HIV-1-specific T cells in DNA-modified vaccinia virus Ankara-vaccinated human volunteers by cultured IFN-gamma ELISPOT assay.
by: Winstone, N, et al.
Published: (2009)

New Candidate Vaccines against Blood-Stage Plasmodium falciparum Malaria: Prime-Boost Immunization Regimens Incorporating Human and Simian Adenoviral Vectors and Poxviral Vectors Expressing an Optimized Antigen Based on Merozoite Surface Protein 1, (vol 78, pg 4610, 2010)
by: Goodman, A, et al.
Published: (2011)

A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory
by: Swadling, L, et al.
Published: (2014)

Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein.
by: Walther, M, et al.
Published: (2006)

The Design and Development of a Multi-HBV Antigen Encoded in Chimpanzee Adenoviral and Modified Vaccinia Ankara Viral Vectors; A Novel Therapeutic Vaccine Strategy against HBV
by: Senthil K. Chinnakannan, et al.
Published: (2020-04-01)

Clinical development of Modified Vaccinia virus Ankara vaccines.
by: Gilbert, S
Published: (2013)

Clinical development of Modified Vaccinia virus Ankara vaccines
by: Gilbert, S
Published: (2013)

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.
by: McShane, H, et al.
Published: (2004)

Therapeutic vaccination against hepatitis B virus using heterolgous prime boost strategy with DNA and modified vaccinia virus ankara vectors
by: McConkey, S, et al.
Published: (2003)

The design and development of a multi-hbv antigen encoded in chimpanzee adenoviral and modified vaccinia ankara viral vectors; a novel therapeutic vaccine strategy against HBV
by: Chinnakannan, SK, et al.
Published: (2020)

A THERAPEUTIC VACCINE FOR HCV BASED ON NOVEL, RARE, ADENOVIRAL VECTORS
by: Kelly, C, et al.
Published: (2011)

Chimpanzee adenoviral vectors as vaccines – challenges to move the technology into the fast lane
by: Alessandra Vitelli, et al.
Published: (2017-12-01)

Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.
by: Clarisse Lorin, et al.
Published: (2015-01-01)

Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials
by: Pathan, A, et al.
Published: (2007)

Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials.
by: Pathan, A, et al.
Published: (2007)

Preferential targeting of conserved Gag regions after vaccination with a heterologous DNA prime Modified Vaccinia Ankara boost HIV vaccine regime
by: Bauer A, et al.
Published: (2012-09-01)

PHASE I TRIAL OF A HIGHLY IMMUNOGENIC T CELL VACCINE FOR HEPATITIS C VIRUS BASED ON NOVEL ADENOVIRAL VECTORS FROM RARE SEROTYPES
by: Folgori, A, et al.
Published: (2009)

Mucosal immunization with PLGA-microencapsulated DNA primes a SIV-specific CTL response revealed by boosting with cognate recombinant modified vaccinia virus Ankara.
by: Sharpe, S, et al.
Published: (2003)

Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants.
by: Gavin Churchyard, et al.
Published: (2016-01-01)

Improved Host Range Selection for Recombinant Modified Vaccinia Virus Ankara
by: Caroline Staib, et al.
Published: (2003-04-01)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
by: Olga Vladimirovna Orlova, et al.
Published: (2022-09-01)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
by: Volker Sandig, et al.
Published: (2013-11-01)

Immunogenicity and Protective Efficacy of Prime-Boost Regimens with Recombinant Delta ureC hly(+) Mycobacterium bovis BCG and Modified Vaccinia Virus Ankara Expressing M. tuberculosis Antigen 85A against Murine Tuberculosis, (vol 77, pg 630, 2009)
by: Tchilian, E, et al.
Published: (2011)

Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials.
by: Ansar A Pathan, et al.
Published: (2007-10-01)

PHASE I TRIAL OF A HIGHLY IMMUNOGENIC T-CELL VACCINE FOR HEPATITIS C VIRUS BASED ON NOVEL ADENOVIRAL VECTORS FROM RARE SEROTYPES
by: Barnes, E, et al.
Published: (2009)

Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis.
by: Mcshane, H, et al.
Published: (2001)

Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara.
by: Smith, C, et al.
Published: (2005)

Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara.
by: Webster, D, et al.
Published: (2005)

Recombinant modified vaccinia virus Ankara efficiently restimulates human cytotoxic T lymphocytes in vitro.
by: Dorrell, L, et al.
Published: (2000)

Correction: Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials.
by: Ansar A. Pathan, et al.
Published: (2011-01-01)

Transient Host Range Selection for Genetic Engineering of Modified Vaccinia Virus Ankara
by: C. Staib, et al.
Published: (2000-06-01)

The third generation modified vaccinia Ankara vaccine is effective in preventing the transmission of mpox
by: Mingwang Shen, et al.
Published: (2024-10-01)

Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
by: Kaïdre Bendjama, et al.
Published: (2017-09-01)

Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?
by: Malachy I. Okeke, et al.
Published: (2017-10-01)

Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8(+) T-Cell Responses, (vol 78, pg 152, 2010)

Similar Items

Similar Items